April 19, 2016

One antidepressant shown to control weight during 2-year study

Research at Group Health points to bupropion (Wellbutrin) as first choice for overweight and obese patients with depression

SEATTLE—Group Health researchers have found that bupropion (marketed as Wellbutrin) is the only antidepressant that tends to be linked to long-term modest weight loss.

Previously, Group Health researchers showed a two-way street between depression and body weight: People with depression are more likely to be overweight, and vice versa. These researchers also found that most antidepressant medications have been linked to weight gain.

Prior research on antidepressants and weight change was limited to one year or shorter. But many people take antidepressants—the most commonly prescribed medications in the United States—for longer than a year. So for up to two years the new study followed more than 5,000 Group Health patients who started taking an antidepressant. The Journal of Clinical Medicine published it: “Long-Term Weight Change after Initiating Second-Generation Antidepressants.

“Our study suggests that bupropion is the best initial choice of antidepressant for the vast majority of Americans who have depression and are overweight or obese,” said study leader David Arterburn, MD, MPH. He’s a senior investigator at Group Health Research Institute (GHRI), a Group Health physician, and an affiliate associate professor in the University of Washington (UW) School of Medicine’s Department of Medicine. But in some cases, an overweight or obese patient has reasons why bupropion is not for them—like a history of seizure disorder—and it would be better for them to choose a different treatment option.

Study findings

“We found that bupropion is the only antidepressant that tends to be linked to weight loss over two years,” Dr. Arterburn said. “All other antidepressants are linked to varying degrees of weight gain.” 

After two years, nonsmokers lost an average of 2.4 pounds on bupropion—compared with gaining an average of 4.6 pounds on fluoxetine (Prozac). So those who took bupropion ended up weighing 7 pounds less than did those on fluoxetine.

Unsurprisingly, that difference wasn’t seen in people who smoked tobacco. Bupropion is often used to help patients stop smoking. So smokers who take bupropion are likely to be trying to quit—and coping with the weight gain that often accompanies attempts to quit smoking.

Who should try which antidepressant?

“A large body of evidence indicates no difference in how effectively the newer antidepressants improve people’s moods,” said Dr. Arterburn’s coauthor Gregory Simon, MD, MPH, a Group Health psychiatrist, GHRI senior investigator, and research professor in psychiatry and behavioral sciences at the UW School of Medicine. “So it makes sense for doctors and patients to choose antidepressants on the basis of their side effects, costs, and patients’ preferences—and, now, on whether patients are overweight or obese.”

Bupropion should be considered the first-line drug of choice for people who are overweight or obese, Dr. Simon said. But patients should consult their doctor about which medication is right for them, before making any changes, including starting, switching, or stopping medication.

Grant R01 MH083671 from the National Institute of Mental Health funded this research.

Drs. Arterburn and Simon’s coauthors are GHRI Senior Investigator Denise M. Boudreau, PhD, Research Project Management Director Emily O. Westbrook , Programmer Analyst Mary Kay Theis, and Andy Bogart; Tamar Sofer, PhD, a biostatistician at the UW School of Public Health and post-doctoral research fellow at Harvard University; and Sebastien Haneuse, PhD, an associate professor of biostatistics at the Harvard T.H. Chan School of Public Health, who used to work at GHRI.

About Kaiser Permanente

Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America’s leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 12.4 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to: kp.org/share.

Co-researchers

Gregory E. Simon, MD, MPH

Senior Investigator

KPWHRI; Psychiatrist, Washington Permanente Medical Group

,




Media contact

For more on Kaiser Permanente Washington Health Research Institute news, please contact:

Caroline Liou
caroline.x.liou@kp.org

206-947-4560
After-hours media line: 206-448-4056

page-twitter-icon.png @KPWaResearch


Media contact

For more on Kaiser Permanente Washington Health Research Institute news, please contact:

Amelia Apfel

Amelia.X.Apfel@kp.org

(425) 507-5455
After-hours media line: (206) 287-2055

page-twitter-icon.png @KPWaResearch

healthy findings blog

scale-1col.jpg

Weight controlled better with bupropion (Wellbutrin) than with other antidepressants

Dr. David Arterburn describes his research on Group Health patients’ weight after 2 years on various antidepressants.

Read it in Healthy Findings.